En comparacin directa, tirzepatida demostr superioridad sobre semaglutida en reduccin de peso y control glucmico
Crockett Chair in Diabetes Research, medical director of AdventHealth Diabetes Institute and a Healio | Endocrine Today Co-editor, described the FLOW findings as practice changing. Pratley said while the American Diabetes Association Standards of Care recommends SGLT2 inhibitors as the first-line treatment for most adults with type 2 diabetes and CKD, the FLOW trial may change that in the future
At minimum: baseline IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel, and a full hormone panel
Its necessary for the formation of red blood cells and DNA
1520 minutes after activity can reduce inflammation
This information is for educational and informational purposes only